Your browser doesn't support javascript.
loading
Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma.
Wang, Jeffrey; Wang, Jacqueline; Lopez, Elyse; Guo, Hui; Zhang, Hui; Liu, Yang; Chen, Zhihong; Huang, Shengjian; Zhou, Shouhao; Leeming, Angela; Zhang, R J; Jung, Dayoung; Shi, Hannah; Grundman, Hadley; Doakes, Darian; Cui, Kathleen; Jiang, Changying; Ahmed, Makhdum; Nomie, Krystle; Fang, Bingliang; Wang, Michael; Yao, Yixin; Zhang, Liang.
Afiliação
  • Wang J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang J; Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lopez E; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Guo H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Liu Y; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen Z; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Huang S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhou S; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Leeming A; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang RJ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jung D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shi H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Grundman H; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Doakes D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cui K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jiang C; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ahmed M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nomie K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fang B; Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yao Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Blood Cancer J ; 9(12): 95, 2019 11 28.
Article em En | MEDLINE | ID: mdl-31780660
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Proteína Supressora de Tumor p53 / Auranofina / PTEN Fosfo-Hidrolase / Mutação / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma de Células B / Proteína Supressora de Tumor p53 / Auranofina / PTEN Fosfo-Hidrolase / Mutação / Antineoplásicos Idioma: En Ano de publicação: 2019 Tipo de documento: Article